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Objective: Although twin and family studies have shown attention-deficit/hyperactivity 
disorder (ADHD) to be highly heritable, genetic variants influencing the trait at a genomewide 
significant level have yet to be identified. Thus additional genomewide association 
studies (GWAS) are needed. Method: We used case-control analyses of 896 cases with 
DSM-IV ADHD genotyped using the Affymetrix 5.0 array and 2,455 repository controls 
screened for psychotic and bipolar symptoms genotyped using Affymetrix 6.0 arrays. A 
consensus SNP set was imputed using BEAGLE 3.0, resulting in an analysis dataset of 
1,033,244 SNPs. Data were analyzed using a generalized linear model. Results: No genomewide 
significant associations were found. The most significant results implicated the following 
genes: PRKG1, FLNC, TCERG1L, PPM1H, NXPH1, PPM1H, CDH13, HK1, and HKDC1. 
Conclusions: The current analyses are a useful addition to the present literature and will 
make a valuable contribution to future meta-analyses. The candidate gene findings are 
consistent with a prior meta-analysis in suggesting that the effects of ADHD risk variants 
must, individually, be very small and/or include multiple rare alleles. J. Am. Acad. Child 
Adolesc. Psychiatry, 2010;49(9):906 –920. Key Words: ADHD, genetics, genome-wide association, 
Imputation 
 
 
 
 
Attention-deficit/hyperactivity disorder (ADHD) is among the most common childhood onset psychiatric disorders. The 
worldwide prevalence of ADHD in children is 8% to 12%1 and the prevalence of ADHD in adults in the United States 
is approximately 4%.2,3 Early studies found the risk of ADHD among parents of children with ADHD to be increased 
by between two- and eightfold, with similarly elevated risk among the siblings of ADHD subjects (for a review of this 
literature, see Faraone and Biederman 4). Faraone et al.5 extended these findings to families ascertained via adult 
probands meeting criteria for either full DSM-IV ADHD or late-onset ADHD. 
  
Adoption and twin studies are necessary to disentangle genetic from environmental sources of transmission observed 
in family studies. Three studies found that biological relatives of ADHD 6 or hyperactive children 7,8 were more likely 
to have hyperactivity than adoptive relatives. A more direct method of examining the heritability of ADHD is to study 
twins: the extent to which monozygotic twins are more concordant for ADHD than dizygotic twins can be used to 
compute the degree to which variability in ADHD in the population can be accounted for by genes (i.e., heritability). 
Reviews of twin studies from the United States, Australia, Scandinavia and the European Union show heritability for 
ADHD to be approximately 75%, which places it among the most heritable of psychiatric disorders.9–11 
  
Candidate gene association studies have focused heavily on catecholaminergic pathways,16–20 the major target of most 
pharmacotherapies for ADHD.21 However, genes within the serotonergic and neuro-developmental pathways have also 
been examined. A meta-analysis found nominally significant (p < .05) associations at the following: SLC6A3/DAT1 (3'UTR 
VNTR and rs27072), DRD4 (exon 3 VNTR and rs1800955), DRD5 (148-bp allele), SLC6A4/5HTT (5HTTLPR), HTR1B 
(rs6296), and SNAP-25 (rs3746544)16; however, these effects, if present, are likely to be small and have not been 
unequivocally confirmed by prior genome-wide association scans of ADHD.22–25 
  
The present work continues the search for ADHD susceptibility genes by completing a new, independent, multi-site case-
control genome-wide association study (GWAS) of DSM-IV ADHD, using the Affymetrix 5.0 and 6.0 arrays.  
In an attempt to find regions of chromosomes that might harbor genes for ADHD, several groups have conducted 
genome-wide linkage scans. This approach examines many DNA markers across the genome to determine whether 
any chromosomal regions are shared more often than expected among ADHD family members. These have produce 
mixed results, with some reporting evidence of linkage 12,13 and others not.14 To determine whether there were any 
significant linkage signals among these studies, Zhou et al.15 conducted a genome scan meta-analysis of these data. 
They reported genome-wide significant linkage (pSR = .00034, pOR = .04) for a region on chromosome 16 between 
64 Mb and 83 Mb. Although this finding is intriguing and worthy of follow-up, the lack of significant findings for other 
loci suggests that many genes of moderately large effect are unlikely to exist, and that the method of association will 
be more fruitful in the search for ADHD susceptibility genes. 
 
 
 
Method 
Participants   
The 1,150 cases used in the present analysis consist of (a) samples collected by a subset of the International 
Multicenter ADHD Genetics (IMAGE) Project sites but not included in the IMAGE GWAS 23; and (b) samples 
collected at additional sites (Frankfurt/Homburg, Trier, Wuerzburg, Germany, Scotland, and Cardiff, United 
Kingdom) that were assessed in a manner similar to IMAGE samples. Cases were identified mainly through 
outpatient clinics at the data collection sites. They were predominantly of European origin from the United 
Kingdom, Ireland, Germany, the Netherlands, and the United States. Of the cases, 81% met criteria for DSM-IV 
ADHD. Children had been referred for assessment of hyperactive, disruptive or disorganized behavior and had 
been clinically diagnosed as ADHD (or hyperkinetic disorder, the most closely equivalent category in the ICD-10 
nomenclature used at some of the clinics). Clinical and demographic features of the case sample stratified by 
site are provided in Table 1. All case data were collected with informed consent of parents and with the approval 
of the site's institutional review board or ethical committee. 
   
  
 
At the IMAGE sites, parents of children were interviewed with the Parental Account of Childhood Symptom 
(PACS), a semi-structured, standardized, investigator-based interview developed as an instrument to provide 
an objective measure of child behavior. Both parents and teachers completed the respective versions of the 
Conners ADHD rating scales and the Strengths and Difficulties Questionnaire. Exclusion criteria were 
autism, epilepsy, IQ <70, brain disorder, and any genetic or medical disorder associated with externalizing 
behaviors that might mimic ADHD. 
  
In Germany, families were recruited in order of clinical referral in the outpatient clinics in Wuerzburg, 
Homburg, and Trier. Families were of German white ancestry. All cases met DSM-IV criteria for ADHD. The 
index child was 6 years or more of age, and further affected siblings were included when at least 6 years of 
age. All children were assessed by full semistructured interview (Kiddie-Sads-PL-German Version or Kinder-
DIPS) and parent and teacher ADHD DSM-IV–based rating scales to ensure pervasiveness of symptoms. 
Exclusion criteria were IQ < 80, comorbid autistic disorders or somatic disorders (e.g., hyperthyroidism, 
epilepsy, neurological diseases, severe head trauma), primary affective disorders, Tourette syndrome, 
psychotic disorders or other severe primary psychiatric disorders, and birth weight <2,000 g. 
 
At the Cardiff site, children ages 6 to 16, of British, Caucasian ancestry, were assessed by interviewing 
parents with the Parent Child and Adolescent Psychiatric Assessment (CAPA)-a semi-structured research 
diagnostic interview and a telephone interview with the teacher using the Child ADHD Teacher Telephone 
Interview. All cases met diagnostic criteria for DSM-IV ADHD or ICD-10 hyperkinetic disorder or DSM-III-R 
ADHD and had IQ test scores above 70. Exclusion criteria were pervasive developmental disorder, Tourette 
  
syndrome, psychosis or any neurological conditions. 
TABLE 1 Clinical and Demographic Characteristics of the Case Sample, Stratified by Site 
 
At the Scottish site, children ages 6 to 16 years, of British white ancestry, were assessed by interviewing 
parents with the Parent Child and Adolescent Psychiatric Assessment (CAPA), a semistructured research 
diagnostic interview. To confirm pervasiveness, teachers completed the Conners Teacher Rating Scale. All 
cases met diagnostic criteria for DSM-IV ADHD. Children with an IQ <70, autistic spectrum disorder, head 
injury, known chromosomal abnormality, encephalitis or significant medical conditions such as epilepsy were 
excluded. 
  
The control sample (2,653 population controls of European ancestry) was collected for an institutional review 
board–approved GWAS of schizophrenia and have been described elsewhere.26 Briefly, the control 
participants were drawn from a US nationally representative survey panel (of approximately 60,000 adult 
individuals at any one time, with constant turnover) ascertained via random digit dialing. Participants were 
screened for psychosis and bipolar disorder. Control participants were not screened for ADHD. A blood 
sample was collected via a US national phelbotomy service. Control participants gave written consent for 
their DNA to be used for medical research at the discretion of NIMH. 
 
 
 
  
Genotyping 
Cases were genotyped using the Affymetrix 5.0 array at the State University of New York Upstate Medical University, 
Syracuse using the standard protocol issued by Affymetrix. The genotypes were called using both BRLMM-P and 
BIRDSUITE,27 with any calling discrepancies coded as missing. Controls were genotyped using the Affymetrix 6.0 
array, at the Broad Institute National Center for Genotyping and Analysis. Genotype calls were made with the 
BIRDSEED program, a module of the BIRDSUITE package. 
  
The control genotype data initially quality controlled by the National Center for Biotechnology Information (NCBI). The 
quality control (QC) of the control data has been described in detail elsewhere.26 Briefly, the 2,653 control samples 
used in the present analyses had call rates >97%, genders consistent with site reports, and 26% to 28.5% 
heterozygous genotypes, and were of European ancestry (as evaluated by EIGENSTRAT). The prior data-cleaning 
efforts for this set of genotypes include SNP call rate <95%, Hardy–Weinberg equilibrium, p value <10-6, MAF <1%, 
plate effects, and removal of SNPs showing more than two Mendelian errors (from a set of trios that are not included 
in these analyses) or discordant genotypes for duplicate samples. 
 
QC and Statistical Analyses 
  
As the cases and controls were genotyped using different platforms, we undertook additional QC checks before 
conducting imputation. To ensure imputation quality, we applied more stringent QC exclusion thresholds and carefully 
examined differences between cases and controls. Our key criterion for QC consideration was call rate at the sample 
and SNP levels, as well as call rate differences between cases and controls. These sample and SNP exclusion criteria 
are found in Table 2. 
TABLE 2 Summary of Case and Control Quality Control (QC) Filtering and Exclusion Criteria, in Order of Operation 
 
  
   
In the first stage of QC, the case and control samples were screened for low call rate, low MAF, allele frequency 
differences relative to the European–American and Toscani Italian HapMap samples (CEU and TSI). The two 
datasets were then merged, resulting in a dataset of 896 cases and 2,455 controls, genotyped on 340,536 SNPs 
common to both samples. To define the set of SNPs which were included in the analysis, we conducted a first pass 
case/control analysis in PLINK 28 and examined the distribution of association test statistics, with a particular focus on 
the [lambda] statistic (defined as the observed median [chi]2 divided by the expected median [chi]2). We observed a 
relatively high [lambda] of 1.20. A strong correlation was also observed between significance values and call rate. This 
relationship was more pronounced for SNPs where call rate differences were observed between cases and controls. 
  
Based on these results, we undertook a further round of QC excluding SNPs with a call rate <99%, call rate difference 
case-control >0.5%, MAF <1. This led to the exclusion of an additional 76,334 SNPs. We also increased the 
stringency of call rate at the individual level to 98%, which excluded an additional six cases. We chose these 
exclusion thresholds because SNPs in the excluded categories had a much higher rate of missingness than other 
SNPs, which could lead to spurious evidence for association. The resulting [lambda] was 1.16 with only little evidence 
for technical inflation of test statistics, as indicated by further metadata such as call rate and Hardy–Weinberg 
equilibrium p value. 
 
With the merged dataset, before QC, we estimated genome-wide identity by descent using PLINK, which derives this 
information from the pairwise identity-by-state patterns within the data. Based on these results, we excluded an 
additional 52 cases (seven avuncular/halfsibs, 35 siblings, 10 identical). To further examine population substructure 
within our sample, we applied the multidimensional scaling algorithm (MDS) in PLINK to a linkage disequilibrium 
pruned sample, after cleaning. This MDS algorithm is numerically equivalent to the principal component analysis 
implemented in Eigenstrat. These units represent the contribution of many hundreds to thousands of SNPs, which 
share covariance induced by technical artifacts or, more commonly, population stratification. The main plot in Figure 1 
shows the first two multidimensional scaling dimensions (PCA1 and PCA2). As shown in Figure 1, the majority of 
subjects were tightly clustered, indicating that most of the subjects were of European ancestry. The following 
exclusion criteria were applied based on visual inspection of the MDS plots: MDS dimension 1 > 0.01; MDS dimension 
2 > 0.01 and < -0.01; and MDS dimension 4 < -0.02. 
 
 
 
 
 
 
 
 
 
FIGURE 1 Population substructure within the case (red dots) and control (black dots) as assessed by 
multidimensional scaling. Note: PCA1 _ first multidimensional scaling dimension. 
 
 
Based on these thresholds, an additional 274 (198 controls, 76 cases) samples were excluded from the analysis. 
Thus the final sample consisted of 3,357 individuals (896 cases, 2,455 controls), genotyped on 226,110 SNPs. The 
[lambda] value arising from a PLINK case-control analysis was calculated as 1.08, suggesting that the methodological 
and technical confounds have mostly been accounted for. These data were then imputed using BEAGLE 3.0,29–31 
using the HapMap 3 phased CEU and TSI samples as a reference (410 haplotypes).32,33 The imputation procedure 
was conducted jointly on cases and controls. 
  
To restrict the analysis to well imputed SNPs, we applied a threshold of 0.6 to the quality score, resulting in an 
analysis dataset of 1,033,244 SNPs. The quality score was defined as the ratio of the variance of the dosages, as 
compared with the variance that is predicted from the allele frequency. This can be interpreted as the proportion of 
information generated by imputing versus genotyping the variant. 
 
Statistical Analyses 
  
After the QC, we conducted association analysis using a generalized linear model (GLM) in R, using the 10 principal 
components from the MDS procedure as covariates. This model removes most of the effects of population 
stratification and any residual technical bias, which helps to control for false-positive results. The p value reported is 
the Wald statistic from the GLM, which is asymptotically distributed as a chi-square with 1 degree of freedom under 
the null hypothesis. 
 
Results 
  
Because genotyping artifacts and ethnic differences between populations can confound GWAS analyses, it is 
essential to show the absence of artifacts. We do this with the quantile–quantile (QQ) plot in Figure 2, which plots, for 
each SNP, the observed versus expected p value. In the presence of spurious associations, evidence for association 
would be seen across all SNPs, i.e., the plotted line would be above the diagonal line throughout the range plotted. 
We see some inflation above the diagonal, but this is small as measured by a lambda statistic ([lambda]) of 1.08, 
which is not much greater than the value of 1.0 expected when there is no inflation. Thus, the QQ plot suggests that 
our QC procedures removed most association signals that could be attributed to either technical artifacts or population 
stratification. We further examined the distribution of test statistics and [lambda] by imputation status (genotyped vs. 
imputed) and by minor allele frequency (using 10 equally spaced bins). There was no obvious correlation of inflation of 
test statistics with either MAF or imputation status. Similarly there was no relationship between quality score and the 
distribution of the test statistic. 
FIGURE 2 Quartile– quartile plot of genome-wide association of attention-deficit/hyperactivity disorder. 
 
 
 
As shown in Figure 3, the strongest signal was observed on chromosome 10 (10q21.1; p = 6.32e-07) driven by 
rs10823973 (C/G). The association signal from this SNP is supported by association from SNPs with which it is in 
strong LD. In this sample, the C allele was more common in cases than in controls, with a frequency of 57.8% in 
cases and 51.2% in controls. The SNP is located in PRKG1. As Figure 4 shows, the association signal is also 
seen for nearby SNPs in the region, which suggests that the association is true rather than being caused by 
technical artifact or population stratification. This result lies in a well-established chromosome 10 inversion,34 
spanning 10q11.2 to 10q21. 
FIGURE 3 Manhattan plot from the genome-wide generalized linear model (GLM) analysis. Note: ADHD _ 
attention-deficit/hyperactivity disorder; Chr _ chromosome; GWAS _ genome-wide association study. 
 
 
 
 
 
 
 
 
FIGURE 4 Regional association and linkage disequilibrium (LD) plot for the 10q21.1 region. Note: The most 
associated genotyped single-nucleotide polymorphism (SNP) is shown in the diamond in bright red, and the color 
of the remaining markers reflects the linkage disequilibrium (r 2) with the top single-nucleotide polymorphism 
(SNP) in each panel (increasing red hue associated with increasing r 2). The recombination rate (right-hand y 
axis) is plotted in light blue and is based on the European–American (CEU) HapMap Phase III population. 
 
 
 
The next strongest signals were located on chromosomes 20q13.33 (rs17729098, p= 1.68e-06) and 7q31.1 
(rs2291567, p = 1.97e-06). The association signal on chromosome 20 is likely artifactual, as there are no other 
SNPs in the region that show similar levels of association (Figure 5a), although this conclusion is limited by the 
poor coverage of SNPs in the region. The chromosome 7 finding, on the other hand, does show a broad region of 
association suggesting that this is not due to a technical artifact or population stratification (Figure 5b). We also 
examined the results for SNPs in the 18 genes considered in a recent meta-analysis.16 However, none of these 
SNPs were significant at a level of p <= .001. 
 
 
 
 
 
FIGURE 5 (A) Regional association and linkage disequilibrium (LD) plot for 20q13.33 region. (B) Regional 
association and LD plot for 7q32.1 region. 
 
 
 
 
Table 3 presents the top 100 hits based on p value significance in our imputed dataset. The table indicates the 
gene name of the SNP fall within a gene. We and colleagues from three other GWAS Consortia have completed a 
meta-analysis that includes the data presented in this paper.35 That meta-analysis comprised 2,064 trios, 896 
cases, and 2,455 controls. In Table 3, we also give the p value for each SNP from the meta-analysis. 
 
 
 
 
 
 
 
TABLE 3 Top 100 Single-Nucleotide Polymorphisms (SNPs) from Imputed International Multicenter ADHD 
Genetics Project (IMAGE) II dataset 
 
 
 
 
 
 
 
Discussion 
  
We have reported an independent genome-wide association scan of ADHD. None of the SNPs achieved 
genome-wide significance (p < 5.0e-08), either in the sample reported here or in a meta-analysis or our results 
with other samples.35 Given the extent to which ADHD is genetic, it is highly likely that within the set of SNPs 
with p value <10
-3
 there are true associations for which we do not yet have sufficient power to unequivocally 
detect. 
  
Although no finding achieved genome-wide significance, several of our top findings deserve further comment. 
The PRKG1 gene regulates neuronal migration, signal transduction, dendrite development, long-term 
potentiation, and forebrain development.36–39 Thus, it is a reasonable candidate for a gene that might lead to 
brain abnormalities and ADHD. 
  
One of our top findings was in the CDH13 gene (p = 2.28E-05). CDH13 was implicated by a GWAS of 343 
ADHD adults and 250 controls 22 and in the IMAGE GWAS of ADHD symptom counts.24,25 This gene lies 
under a linkage peak implicated in a meta-analysis of ADHD linkage studies 15 and has been implicated in 
substance use disorders,40 which co-occur with ADHD.41,42 
  
Column 7 of Table 3 helps with the interpretation of our findings in the context of other ADHD GWAS. This 
column gives the p value from a meta-analysis 35 that comprises the data in this paper and data from three 
other consortia: IMAGE,23 PUWMa 43 and CHOP (unpublished data). As seen in Table 3, most SNPs show a 
dramatically higher p value on the combined sample. No SNP increases in significance, and a few retain 
significance levels <.0001. This does not create confidence in the idea that many of our top 100 SNPs are true 
associations. 
  
Our negative results indicating the existence of very small genetic effects when individual variants are 
considered alone is not surprising. GWAS findings are now emerging for other psychiatric disorders. There have 
been replicated copy number variation associations for schizophrenia 44,45 and for autism,46–48 a genome-
wide significant association for bipolar disorder,49 and a significant association from a schizophrenia–bipolar 
dataset.50 These early GWAS results suggest that, because of the many statistical comparisons required to 
scan the genome, large samples are needed to detect some genes, and extremely large samples are needed to 
detect many genes. 
 
For example, the successful bipolar disorder GWAS, which detected two loci at genome-wide levels of 
significance, required 4,387 cases and 6,209 controls.49 Studies of this size and larger implicated several genes 
for diabetes,51 but a pooled sample of 60,000 subjects was required to definitively implicate a large set of 
genes.52 For type 2 diabetes and Crohn's disease, mapping of one or a small number of disease-associated 
variants was successful in studies with sample sizes similar to that of the present study; however the vast 
majority of findings have emerged with the incorporation of multiple scans involving sample sizes many times 
larger than that presented here,52,53 and in most cases consisted of genetic loci conferring odds ratios in the 
region of 1.1 to 1.4. The statistical requirement for large sample size for GWAS should not be interpreted as 
meaning that the effects of individual genetic variants are very much smaller than the effects of individual 
environmental variants; in fact, the latter are small as well.54 
  
The general expectation from GWAS of complex disorders is for multiple genes of very small effect.55 Backward   
power calculations on some of the initial true results from these diseases indicate that many of the identified 
candidates were extremely unlikely to be detected from the initial study.55 Thus these initial studies were either 
fortunate or many such effects (potentially 100 or more) with a similar effect size must exist. In this study we 
have not been fortunate, insofar as we did not identify a variant above genome-wide significance, which we 
define as 5 × 10-8.56,57 Concerning the existing candidate genes for ADHD, the genome-wide association data 
do not provide genome-wide significant support for any of the previously postulated candidates. That is not to 
say that these genes should be rejected from consideration, but rather that the effect sizes for each of these 
variants must be small if they are real effects, which is consistent with the meta-analyses of candidate gene 
studies.10,11,16 
We have considered the pathophysiological and clinical implications of genetic effects so small that they cannot 
be detected with our current sample size. Such small effects can arise for several potential reasons. First, it may 
be correct that genetic risks for ADHD are due to numerous small additive effects of common risk variants; 
however, it is also possible that multiple rare variants of small to moderately large effect size could account for 
these findings.58 Alternative explanations include sample heterogeneity, the possible interaction of genetic 
variants either within or between genes, and their interaction with environmental risk factors. Although the 
heritability of ADHD is high, this does not give an indication of the underlying genetic architecture, although it 
does imply that genetic influences are important for the etiology of the disorder. Recent modeling of complex 
behavioral and biological traits in the mouse suggests that as heritability increases the number of genetic 
variants involved increases, although effect sizes of individual variants remain small.59 For ADHD, our 
expectation is that novel genes for ADHD will be identified from GWAS once sufficient whole-genome 
association data have been accumulated from the analysis of 5,000 to 10,000 cases. 
  
Given the expense of GWAS, it is reasonable to ask whether genes of very small effect are worth discovering. 
Theoretical considerations suggest that the smallness of a gene effect should not be confused with the potential 
importance of its discovery. For example, should we someday discover a rare variant or a common variant of 
small effect that implicates a new biological pathway in ADHD, that pathway could then be searched for 
biological targets that might yield treatments which are more efficacious than standard therapies for the disorder. 
The discovery of such a variant would also focus research on the implicated gene and pathway, which could 
lead the discovery of similar variants. 
  
The need to search for DNA variants that lead to ADHD cannot be understood without placing the disorder in the 
context of current knowledge. ADHD is a common disorder affecting up to 10% of children.1 In the majority of 
cases, the disorder persists into adulthood 60 and is associated with serious impairments including traffic 
accidents,60 increased health care use,60 substance abuse,60 unemployment,60 divorce,60 and risk behaviors 
for acquired immunodeficiency syndrome (AIDS).61 Approximately 25% of ADHD patients do not respond well 
to currently available therapies.62,63 Moreover, the currently preferred treatment for ADHD is stimulant 
medication. Although medications for ADHD are effective in controlling symptoms for many patients, they do not 
  
“cure” the disorder. Even those patients who are receiving treatment are at risk for adverse outcomes.64 
Currently available treatments improve outcomes but leave patients with much residual disability and do not 
markedly improve the executive dysfunction seen in many ADHD patients. These treatments also have adverse 
effects, including delays in growth.65 
The outcome of the present study may have been influenced by a number of limitations. Most notably is the 
issue of power. We had 80% power for an odds ratio of 1.65, assuming a multiplicative model and a 10% minor 
allele frequency. Thus we did not have sufficient power to detect smaller effects or the same effect at lower 
allele frequencies. Much larger samples or meta-analyses of the current samples will provide a stronger strategy 
for advancing knowledge regarding the molecular genetics of ADHD along with paradigms designed to search 
for rare genetic variants. Another limitation of the current study was the differences in genotyping platforms used 
to analyze case and control samples. This design limitation lead to the exclusion of numerous SNPs through 
additional QC steps before imputation. Although it is possible that this might lead to artificial inflation of the test 
statistics, it is unlikely that this had much influence on the outcome of the study, given the relatively low genomic 
control value and the lack of significant results. 
  
Imputation analysis, albeit extremely useful at generating estimates of association evidence at genetic loci that 
have not been typed, is not perfect. The uncertainty inherent in these analyses reduces the effective sample 
size, thus limiting power. Also, imputation, like genome-wide association, has limited capacity for the analysis of 
rarer variation. These analyses used population-based controls that were not screened for ADHD. Although this 
will have reduced power somewhat, given the prevalence of the disorder, we do not expect that this had much 
impact on the results. Finally, ADHD very likely is genetically heterogeneous, such that many different genetic 
architectures give rise to similar clinical presentations. This includes the possibility that rare variants account for 
part of the disorder's heritability. Such genetic heterogeneity and complexity reduces power to detect significant 
association. 
  
In summary, although the current analyses have not identified any convincing results the sample is a useful 
addition to the present literature and has made a valuable contribution to the current meta-analysis of ADHD 
GWAS,35 which combines data from four ADHD GWAS. 
  
We thank the patients and the family members who provided data and the research coworkers who helped 
collect, manage and discuss data, especially Mick O'Donovan, Kate Langley, Michael Owen, Peter Holmans, 
and Nigel Williams, all of Cardiff University. 
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